Insmed Incorporated (INSM) Announces Positive Open Label Data From Phase 2 Clinical Trial Of ARIKAYCE For Treatment Resistant Nontuberculous Mycobacterial Lung Infections
5/20/2014 10:00:16 AM
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Insmed Incorporated (Nasdaq:INSM) today announced additional results from the Company’s phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. The results are highlighted in a poster entitled, “A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (ARIKAYCE) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease,” that will be presented today at the American Thoracic Society’s Annual Meeting 2014 in San Diego, California by Kenneth N. Olivier, M.D., M.Ph., National Institute of Allergy and Infectious Diseases and a co-Principal Investigator of the study. The poster is available on the Company’s website at www.insmed.com.
Help employers find you! Check out all the jobs and post your resume.
comments powered by